《高盛认股证牛熊证》市场忧虑药监局新政 医药股急跌 留意贴价药明购23249，贴价复医购15172
国家药品监督管理局药品审评中心上周五公布新「关於公开徵求《以临床价值为导向的抗肿瘤药物临床研发指导原则》意见的通知」，指药物进行临床对照试验时应尽量为受试者提供临床实践中最佳治疗方式及药物。及指新药研发应以为患者提供更优治疗选择为最高目标。市场预期在新政策令药物研发企业需达更高要求之下，或可能面对订单数量减少的情况。
医药股今早急跌，当中自上周二起连跌的药明生物(2269)，今早低开约1%後跌幅扩大，最低见116.5元，为半个月低位。现报121.4元，跌约12%，为连续第五日下跌。亦於上周二起连跌的复星医药(2196)，今早持平开市後随即下跌，最低见54.8元。现报55.3元，跌约11.3%，亦为连续第五日下跌。
观察轮证资金流向，可见近日药明认购证获资金转向，上周五及本周一共录得约130万元资金流入。
投资者如看好药明，可留意属行使价121至160元间、2个月期以上的认购证中，杠杆最高之一的贴价药明购23249。
药明购23249，行使价139.98元，2021年09月29日到期，实际杠杆6.3倍，贴价、行使价121至160元间、2个月期以上产品中，杠杆最高之一
投资者如看好复星，可留意年期约5个月，属贴价的复医购15172。
复医购15172，行使价61.93元，2021年11月23日到期，实际杠杆3.6倍，贴价
高盛医药股轮证精选：
药明购23249，行使价139.98元，2021年09月29日到期，实际杠杆6.3倍
药明牛66979，收回价105元，行使价103.5元，换股比率100，杠杆比率6.9倍
复医购15172，行使价61.93元，2021年11月23日到期，实际杠杆3.6倍
石药购23575，行使价10.9元，2021年09月27日到期，实际杠杆8.1倍
国药购24483，行使价30元，2021年11月30日到期，实际杠杆6.5倍
中药牛53431，收回价6.88元，行使价6.48元，换股比率10，杠杆比率10.7倍
注: 以上数据资料来自高盛认股证牛熊证网站https://www.gswarrants.com.hk/~
重要声明:
以上资讯由第三方提供，AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告，不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料，本公司亦不负品质保证之责任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
